Compounds, oncolytics, and pharmaceutical compositions

Compounds inhibiting Golgi mannosidase with reduced cytotoxicity address the high toxicity issue of existing agents, enabling effective tumor disruption and improved anticancer drug delivery.

JP2024158500APending Publication Date: 2024-11-08NIHON UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023073745
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing oncolytic agents targeting Golgi mannosidase inhibitors exhibit high toxicity and cytotoxicity, making them unsuitable for effective cancer treatment due to increased side effects from high doses required to penetrate solid tumors.

Method used

Development of compounds represented by specific general formulas (a0) and (a1) that inhibit Golgi mannosidase activity, reducing cytotoxicity and enhancing tumor penetration, thereby suppressing tumor cell adhesion and facilitating deeper delivery of anticancer drugs.

Benefits of technology

The compounds achieve reduced cytotoxicity, allowing for effective tumor disruption at lower concentrations, reducing side effects and enhancing the efficacy of anticancer drugs by improving their delivery to the tumor core.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158500000025
    Figure 2024158500000025
  • Figure 2024158500000026
    Figure 2024158500000026
  • Figure 2024158500000027
    Figure 2024158500000027
Patent Text Reader

Abstract

To provide: compounds that can inhibit adhesion between tumor cells and have reduced cytotoxicity; oncolytics that contain the compounds or salts thereof, or solvates thereof, as active ingredients; and pharmaceutical compositions containing such oncolytics.SOLUTION: A compound represented by the general formula (a0) is selected. In the formula, R1 is an alkoxy group, alkyl group or hydrogen atom; and R2 is a hydrocarbon group which may have substituents.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compounds, oncolytic agents and pharmaceutical compositions. [Background technology]

[0002] Chemotherapy using anticancer drugs is often used in the treatment of cancer. Among cancers, solid cancer cells adhere closely to each other to form cell masses, making it difficult for anticancer drugs to be delivered to the inside of the cell masses. In the treatment of solid cancer, it is necessary to increase the dosage and frequency of the anticancer drug, which results in the problem of side effects being easily caused to patients.

[0003] In response to this, the inventors focused on Golgi mannosidase, which is responsible for constructing cell surface glycans involved in cell adhesion. The inventors found that by contacting solid cancer with a Golgi mannosidase inhibitor, immature N-linked glycans accumulate on the cancer cell surface, inhibiting adhesion between cancer cells and inhibiting the formation of solid cancer (Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Koyama R et al., A novel Golgi mannosidase inhibitor: Molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation, Bioorganic & Medicinal Chemistry, June 2020, Vol. 28, no. 11, 115492. Summary of the Invention [Problem to be solved by the invention]

[0005] However, the Golgi mannosidase inhibitor described in Non-Patent Document 1 has a problem of being highly toxic to cells. Therefore, an object of the present invention is to provide a compound capable of suppressing adhesion between tumor cells and having reduced cytotoxicity, a tumor lytic agent containing the compound or a salt thereof, or a solvate thereof as an active ingredient, and a pharmaceutical composition containing the tumor lytic agent. [Means for solving the problem]

[0006] The present invention includes the following aspects. [1] A compound represented by the following general formula (a0):

[0007] [ka] [In the formula, R 1 R is an alkoxy group, an alkyl group, or a hydrogen atom. 2 is a hydrocarbon group which may have a substituent.

[0008] [2] The compound according to [1], which is a compound represented by the following general formula (a1):

[0009] [ka] [In the formula, R 11 R is an alkoxy group having 1 to 3 carbon atoms or a hydrogen atom. 21 is a halogen atom, an alkyl group having 1 to 3 carbon atoms, a halogenated alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a nitro group. n2 is an integer of 0 to 5. When n2 is an integer of 2 or more, multiple R 21 may be the same or different.]

[0010] [3] In the general formula (a1), R 11 is a methoxy group, and R 21 is a halogen atom, a methyl group, a halogenated methyl group, a methoxy group, or a nitro group. [4] A tumor lytic agent comprising the compound or a salt thereof, or a solvate of the compound or salt according to any one of [1] to [3] as an active ingredient. [5] A pharmaceutical composition for treating a tumor, comprising an effective amount of the tumor-dissolving agent described in [4] and a pharma- ceutically acceptable carrier. [6] The pharmaceutical composition according to [5], wherein the tumor is a solid malignant tumor and is used in combination with an anticancer agent. Effect of the Invention

[0011] According to the present invention, it is possible to provide a compound capable of suppressing adhesion between tumor cells and having reduced cytotoxicity, a tumor lytic agent containing, as an active ingredient, the compound or a salt thereof, or a solvate of either, and a pharmaceutical composition containing the tumor lytic agent. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 shows the results of observing cellular glycans using Con-A and SDL after treating OVCAR-3 cells with KIF or DMJ in Experimental Example 2. [Diagram 2] FIG. 1 shows the results of observing the sugar chains of OVCAR-3 cells using Con-A and SDL after the compounds (a1-1) to (a1-8) were allowed to act on the cells in Experimental Example 2. [Diagram 3] FIG. 13 shows the results of evaluating the activity of compounds (a1-1) to (a1-8) in disrupting spheroids after the compounds (a1-1) to (a1-8) were allowed to act on OVCAR-3 cell spheroids in Experimental Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] In this specification and claims, unless otherwise specified, the term "alkyl group" includes linear, branched and cyclic monovalent saturated hydrocarbon groups. The same applies to alkyl groups in alkoxy groups. Unless otherwise specified, the term "alkylene group" includes linear, branched and cyclic divalent saturated hydrocarbon groups. The "halogen atom" includes a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.

[0014] [Compound] In one embodiment, the present invention provides a compound represented by the following general formula (a0) (hereinafter also referred to as compound (a0)).

[0015] [ka] [In the formula, R 1 R is an alkoxy group, an alkyl group, or a hydrogen atom. 2 is a hydrocarbon group which may have a substituent.

[0016] In formula (a0), R 1 is an alkoxy group, an alkyl group, or a hydrogen atom. R 1 Examples of the alkoxy group in the formula (I) include an alkoxy group having 1 to 5 carbon atoms, and preferably an alkoxy group having 1 to 3 carbon atoms. Specifically, a methoxy group, an ethoxy group, an n-propoxy group, an iso-propoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, or a tert-butoxy group is preferred, a methoxy group or an ethoxy group is more preferred, and a methoxy group is even more preferred. R 1 Examples of the alkyl group in the formula include alkyl groups having 1 to 5 carbon atoms, and preferably alkyl groups having 1 to 3 carbon atoms. Specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl groups are preferred, methyl or ethyl groups are more preferred, and methyl is even more preferred.

[0017] In formula (a0), R 2 is a hydrocarbon group which may have a substituent. R 2 The hydrocarbon group in the formula (I) may be a chain hydrocarbon group or a cyclic hydrocarbon group.

[0018] R 2The chain hydrocarbon group in R is linear or branched. 2 The chain hydrocarbon group in may be a saturated aliphatic hydrocarbon group or an unsaturated aliphatic hydrocarbon group, and is usually preferably saturated. 2 The linear hydrocarbon group in R preferably has 1 to 10 carbon atoms, and more preferably has 1 to 6 carbon atoms. 2 The branched chain hydrocarbon group in preferably has 3 to 10 carbon atoms, and more preferably has 3 to 6 carbon atoms. Examples of the linear saturated aliphatic hydrocarbon group include monovalent linear saturated hydrocarbon groups having 1 to 10 carbon atoms. Examples of the linear saturated hydrocarbon groups having 1 to 10 carbon atoms include a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, and a decyl group.

[0019] R 2 The cyclic hydrocarbon group in may be an aliphatic hydrocarbon group or an aromatic hydrocarbon group, and may be a polycyclic group or a monocyclic group. The monocyclic aliphatic hydrocarbon group is preferably a group in which one hydrogen atom has been removed from a monocycloalkane. The monocycloalkane preferably has 3 to 6 carbon atoms, and specific examples thereof include cyclopentane and cyclohexane. The aliphatic hydrocarbon group that is a polycyclic group is preferably a group in which one hydrogen atom has been removed from a polycycloalkane, and the polycycloalkane preferably has 7 to 12 carbon atoms, specific examples of which include adamantane, norbornane, isobornane, tricyclodecane, and tetracyclododecane.

[0020] The aromatic hydrocarbon group is preferably a group in which one or more hydrogen atoms have been removed from an aromatic hydrocarbon ring having 6 to 15 carbon atoms, more preferably a group in which one or more hydrogen atoms have been removed from benzene, naphthalene, anthracene, or phenanthrene, still more preferably a group in which one or more hydrogen atoms have been removed from benzene, naphthalene, or anthracene, particularly preferably a group in which one or more hydrogen atoms have been removed from benzene or naphthalene, and most preferably a group in which one or more hydrogen atoms have been removed from benzene. Alternatively, examples of the aromatic hydrocarbon group include a group in which one or more hydrogen atoms have been removed from an aromatic compound containing two or more aromatic rings (e.g., biphenyl, fluorene, etc.); a group in which one or more hydrogen atoms have been removed from an aromatic hydrocarbon ring having 6 to 15 carbon atoms (aryl group) in which one of the hydrogen atoms has been substituted with an alkylene group (e.g., arylalkyl groups such as benzyl group, phenethyl group, 1-naphthylmethyl group, 2-naphthylmethyl group, 1-naphthylethyl group, and 2-naphthylethyl group), and the like. The alkylene group bonded to the aryl group preferably has 1 to 4 carbon atoms, more preferably 1 or 2 carbon atoms, and particularly preferably 1 carbon atom.

[0021] R 2 When R is a chain-like hydrocarbon group, some or all of the hydrogen atoms of the chain-like hydrocarbon group may be substituted with a monovalent group containing a heteroatom. Examples of the monovalent group include a halogen atom, a nitro group, an amino group, a hydroxyl group, a carboxy group, a nitrile group, and a thiol group. 2 is a chain hydrocarbon group, the methylene group of the chain hydrocarbon group may be substituted with a divalent group containing a hetero atom. Examples of the divalent group include a carbonyl group, -O-, -C(=O)-O-, -OC(=O)-, an amide group, and an imino group.

[0022] R 2is a cyclic aliphatic hydrocarbon group, some or all of the hydrogen atoms of the cyclic aliphatic hydrocarbon group may be substituted with a monovalent group. Examples of the monovalent group include an alkyl group, an alkoxy group, a halogen atom, a halogenated alkyl group, a nitro group, an amino group, a hydroxyl group, an aldehyde group, a carboxy group, a nitrile group, and a thiol group.

[0023] R 2 When is a cyclic aliphatic hydrocarbon group, the carbon atoms constituting the ring skeleton may be substituted with a divalent group containing a heteroatom. Examples of the divalent group include a carbonyl group, -O-, -C(=O)-O-, -OC(=O)-, an amide group, an imino group, or a combination thereof.

[0024] R 2 is an aromatic hydrocarbon group, some or all of the hydrogen atoms of the aromatic hydrocarbon group may be substituted with a monovalent group. Examples of the monovalent group include an alkyl group, an alkoxy group, a halogen atom, a halogenated alkyl group, a nitro group, an amino group, a hydroxy group, an aldehyde group, a carboxy group, a nitrile group, and a thiol group, and a halogen atom, an alkyl group having 1 to 3 carbon atoms, a halogenated alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a nitro group is preferred.

[0025] R 2 When is an aromatic hydrocarbon group, the carbon atoms constituting the ring skeleton may be substituted with a divalent group containing a heteroatom. Examples of the divalent group include a carbonyl group, -O-, -C(=O)-O-, -OC(=O)-, an amide group, an imino group, or a combination thereof.

[0026] The compound represented by the general formula (a0) is preferably a compound represented by the following general formula (a1).

[0027] [ka] [In the formula, R 11R is an alkoxy group having 1 to 3 carbon atoms or a hydrogen atom. 21 is a halogen atom, an alkyl group having 1 to 3 carbon atoms, a halogenated alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a nitro group. n2 is an integer of 0 to 5. When n2 is an integer of 2 or more, multiple R 21 may be the same or different.]

[0028] R 11 R is an alkoxy group having 1 to 3 carbon atoms or a hydrogen atom. 11 Examples of the aryl group include a methoxy group, an ethoxy group, an n-propoxy group, and an iso-propoxy group, and a methoxy group is preferable.

[0029] R 21 is a halogen atom, an alkyl group having 1 to 3 carbon atoms, a halogenated alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a nitro group. 21 From the viewpoint of further reducing the cytotoxicity of the compound represented by the general formula (a1), R 21 is preferably an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a nitro group. The halogen atom is preferably a chlorine atom. Examples of the alkyl group having 1 to 3 carbon atoms include a methyl group, an ethyl group, an n-propyl group, and an iso-propyl group, with a methyl group and an ethyl group being preferred, and a methyl group being more preferred. The halogenated alkyl group having 1 to 3 carbon atoms is a group in which some or all of the hydrogen atoms of an alkyl group having 1 to 3 carbon atoms are substituted with halogen atoms. As the halogenated alkyl group having 1 to 3 carbon atoms, a group in which some or all of the hydrogen atoms of a methyl group are substituted with halogen atoms is preferable, a group in which all of the hydrogen atoms of -CH3 are substituted with halogen atoms is more preferable, and a trifluoromethyl group is even more preferable. As the halogen atom in the halogenated alkyl group, a fluorine atom is preferable. Examples of the alkoxy group having 1 to 3 carbon atoms include a methoxy group, an ethoxy group, an n-propoxy group, and an iso-propoxy group, with a methoxy group and an ethoxy group being preferred, and a methoxy group being more preferred. n2 is an integer of 0 to 5, and an integer of 0 to 2 is preferable. R 21 is preferably at the ortho or para position relative to the sulfur atom bonded to the benzene ring.

[0030] The compound represented by the general formula (a1) is preferably a compound represented by any one of the following formulas (a1-1) to (a1-8) (hereinafter also referred to as compounds (a1-1) to (a1-8)).

[0031] [ka]

[0032] [ka]

[0033] The compound according to the present embodiment is capable of inhibiting the activity of Golgi mannosidase. Golgi mannosidase is broadly classified into GMI and GMII. Examples of GMI localized in the Golgi of human cells include Mannosyl-oligosaccharide 1,2-α-mannosidase IA (GMIA), Mannosyl-oligosaccharide 1,2-α-mannosidase IB (GMIB), and Mannosyloligosaccharide 1,2-α-mannosidase IC (GMIC). There are five types of α-mannosidases, namely, α-Mannosidase II, Mannosidase alpha class 2A member 1 (GMII1), α-Mannosidase II, and Mannosidase alpha class 2A member 2 (GMII2), as GMII localized in the Golgi of human cells. Among these, the compound according to the present embodiment has been confirmed to inhibit GMI. By inhibiting GMI, it is possible to suppress adhesion between tumor cells and to destroy the solid form of the tumor.

[0034] The compound according to the present embodiment described above is capable of suppressing adhesion between tumor cells and destroying the solid morphology of tumors. The reason why the compound according to the present embodiment exerts such an effect is unclear, but is presumed to be as follows. The compound according to the present embodiment inhibits the GMI of tumor cells, thereby causing immature high mannose type glycans to accumulate on the cell surface. As a result, it is believed that adhesion between tumor cells is suppressed and the solid morphology of tumors is destroyed. By applying the compound according to this embodiment to a solid malignant tumor, adhesion between tumor cells is suppressed, and the anticancer drug is easily delivered to the deep part of the tumor, so that it is possible to reduce the dosage of the anticancer drug required for treatment. As a result, it is possible to reduce the side effects caused by the anticancer drug in the subject.

[0035] In the previously reported α-mannosidase inhibitor (Koyama R et al., Bioorganic & Medicinal Chemistry, June 2020, Vol. 28, no. 11, 115492.), the problem was that the concentration range effective for tumor lysis and the concentration range in which cytotoxicity is expressed were close to each other. The compound according to this embodiment has reduced cytotoxicity compared to the conventional α-mannosidase inhibitor, and the difference between the concentration range in which tumors are lysed and the concentration range in which cytotoxicity is expressed is large. Therefore, according to the compound according to this embodiment, it is possible to lyse tumors at a concentration that does not express cytotoxicity. Therefore, it is possible to reduce the side effects caused by the compound according to this embodiment in the administration subject.

[0036] [Method for producing compound (a0)] The compound of the present embodiment can be produced by combining known methods, for example, by the following production method: First, compounds pre01 to pre04 are synthesized using piperonal as a raw material according to the following procedure.

[0037] [ka]

[0038] Piperonal and ethyl cyanoacetate are reacted in a nitrogen atmosphere to obtain compound pre01. The reaction temperature condition is, for example, about 0 to 180°C. The reaction time is, for example, about 30 minutes to 24 hours. Examples of the reaction solvent include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, and toluene. A catalyst may be used in this reaction. Examples of the catalyst include piperidine.

[0039] Next, the compound pre01 is reacted with a compound represented by the following formula (mPh-1) to obtain the compound pre02. The reaction temperature condition is, for example, about 0 to 100° C. The reaction time is, for example, about 5 minutes to 3 hours. Examples of the reaction solvent include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, toluene, etc.

[0040] [ka] [In the formula, R 1 is an alkoxy group, an alkyl group, or a hydrogen atom.

[0041] Then, the compound pre02 is hydrolyzed using sodium methoxide to obtain the compound pre03. The reaction temperature condition is, for example, about 0 to 100° C. The reaction time is, for example, about 10 minutes to 24 hours. Examples of the reaction solvent include ethanol, methanol, and the like.

[0042] Next, compound pre03 is dissolved in N,N-dimethylacetamide, and compound pre04 is obtained by elimination reaction of the carboxy group. The reaction temperature condition is, for example, about 0 to 200° C. The reaction time is, for example, about 10 minutes to 24 hours.

[0043] Next, the compound pre04 is reacted with a compound represented by the following formula (SCl-1) to obtain a compound represented by the formula (a0). The reaction temperature condition is, for example, about 0 to 200°C. The reaction time is, for example, about 10 minutes to 24 hours. A catalyst may be used in this reaction. An example of the catalyst is N,N-diisopropylethylamine (DIEA).

[0044] [ka] [In the formula, R 2 is a hydrocarbon group which may have a substituent.

[0045] In the above-mentioned method for producing the compound (a0), after each reaction is completed, the compound in the reaction solution may be isolated and purified. For the isolation and purification, a conventionally known method can be used, and for example, a suitable combination of concentration, solvent extraction, distillation, crystallization, recrystallization, chromatography, etc. can be used. The structure of the compound obtained as above is 1 H-nuclear magnetic resonance (NMR) spectroscopy, 13 C-NMR spectroscopy, 19 Identification can be achieved by common organic analysis methods such as F-NMR spectroscopy, infrared absorption (IR) spectroscopy, mass spectrometry (MS), elemental analysis, and X-ray crystal diffraction. The raw materials used in each step may be commercially available or may be synthesized.

[0046] [Tumor lytic drugs] In one embodiment, the present invention provides a tumor lytic agent comprising the compound according to the embodiment, or a salt thereof, or a solvate thereof as an active ingredient. As used herein, the term "tumor lytic agent" refers to a compound or composition that acts on a target solid tumor to disintegrate the solid form of the tumor.

[0047] As used herein, tumors include benign and malignant tumors. A benign tumor is a tumor that does not invade surrounding tissues and does not metastasize to distant organs. A malignant tumor is a tumor that invades surrounding tissues and / or metastasizes to distant organs. In the present specification, tumors include epithelial tumors and non-epithelial tumors. Epithelial tumors are tumors formed by epithelial cells that constitute the cell layer facing the outside world. Examples of epithelial cells include skin cells, and cells that cover the surfaces of tubular organs such as the digestive system, respiratory system, urinary system, reproductive system, and breast. Non-epithelial tumors are tumors formed by cells other than epithelial cells. Examples of non-epithelial cells include cells that constitute muscles, fat, blood vessels, nervous tissue, bones, cartilage, blood, etc.

[0048] The tumor targeted by the tumor lytic agent may be either a benign tumor or a malignant tumor. The tumor targeted by the tumor lytic agent may be either an epithelial tumor or a non-epithelial tumor. The tumor targeted by the tumor lytic agent is a solid tumor. A solid tumor means a tumor having a solid form, excluding blood tumors. The target solid tumor may be either a solid malignant tumor or a benign malignant tumor, preferably a solid malignant tumor, more preferably an epithelial solid malignant tumor. Examples of the target epithelial solid malignant tumor include, but are not limited to, breast cancer, lung cancer, gastric cancer, colon cancer, liver cancer, kidney cancer, prostate cancer, bladder cancer, prostate cancer, thyroid cancer, ovarian cancer, uterine cancer, pancreatic cancer, esophageal cancer, malignant melanoma, etc. Examples of the target non-epithelial solid malignant tumor include osteosarcoma, chondrosarcoma, brain tumor, neuroblastoma, etc.

[0049] The salt of the compound according to the embodiment that may be contained in the tumor lytic agent according to the present embodiment is not particularly limited as long as the tumor lytic agent exerts its effect, and examples thereof include hydrochloride, sulfate, hydrobromide, hydroiodide, phosphate, nitrate, benzoate, methanesulfonate, 2-hydroxyethanesulfonate, p-toluenesulfonate, acetate, propanoate, oxalate, malonate, succinate, glutarate, adipate, tartrate, maleate, fumarate, malate, mandelate, and the like. Among these, the salt of the compound according to the embodiment is preferably a pharma- ceutically acceptable salt.

[0050] The solvate of the compound according to the embodiment or a salt thereof that may be contained in the tumor lytic agent according to the present embodiment is not particularly limited as long as the tumor lytic agent exerts its effect, and examples thereof include hydrates, organic solvent solvates, etc. The solvate of the compound according to the embodiment or a salt thereof is preferably a pharma- ceutically acceptable solvate.

[0051] <Other ingredients> The tumor lytic agent according to this embodiment may consist solely of the compound according to the embodiment, or a salt thereof, or a solvate thereof, or may contain other components. The other components are not particularly limited as long as the tumor disintegrating agent exerts its effect, and examples include excipients, bulking agents, binders, wetting agents, disintegrating agents, surfactants, lubricants, dispersing agents, buffering agents, preservatives, solubilizing agents, antiseptics, flavorings, soothing agents, stabilizers, pH adjusters, antioxidants, antiseptics, preservatives, moisturizing agents, skin protective agents, refreshing agents, fragrances, colorants, chelating agents, keratin softening agents, blood circulation promoters, astringents, tissue repair promoters, antiperspirants, plant extract components, animal extract components, oily bases, emulsifiers, emulsion stabilizers, powder components, polymer components, adhesion improvers, film-forming agents, shape retention agents, lubricants, etc.

[0052] <Application> The use of the tumor lytic agent according to this embodiment is not particularly limited as long as it is intended to disrupt part or all of the morphology of a tumor, and may be, for example, incorporated into a pharmaceutical composition for treating a tumor.

[0053] <How to use and amount> The method and amount of use of the tumor lytic agent according to this embodiment are not particularly limited as long as the tumor lytic agent is effective against tumors, and can be appropriately determined by a person skilled in the art.

[0054] According to the tumor disintegrant of this embodiment, it is possible to suppress adhesion between cells in a target tumor and disintegrate the solid form of the tumor. The tumor disintegrant of this embodiment is characterized by containing compound (a0) or a salt thereof, or a solvate thereof as an active ingredient. Compound (a0) has reduced cytotoxicity compared to the previously reported α-mannosidase inhibitor (Koyama R et al., Bioorganic & Medicinal Chemistry, June 2020, Vol. 28, no. 11, 115492.), and can induce tumor disintegration at a concentration lower than the cytotoxicity expression concentration range. Therefore, even if a tumor disintegrant is administered to a target individual having a tumor, it is possible to reduce the side effects caused by the tumor disintegrant in the target individual.

[0055] The tumor disintegrant according to this embodiment may be used in combination with an anticancer agent to treat solid malignant tumors. By making the compound according to this embodiment act on solid malignant tumors, the anticancer agent can be easily delivered to the deep part of the tumor, so that the dose of the anticancer agent required for treatment can be reduced. As a result, the side effects caused by the anticancer agent can be reduced in the subject of administration.

[0056] [Pharmaceutical composition] In one embodiment, the present invention provides a pharmaceutical composition for treating a tumor, comprising an effective amount of an oncolytic agent according to the embodiment, and a pharma- ceutical acceptable carrier.

[0057] The pharmaceutical composition according to this embodiment may contain a pharma- ceutically acceptable carrier in addition to the tumor lytic agent described above. The term "pharma-ceutically acceptable carrier" refers to a carrier that does not inhibit the physiological activity of the active ingredient and does not show substantial toxicity to the subject of administration. The term "not substantially toxic" refers to the fact that the ingredient does not show toxicity to the subject of administration at the dose normally used. In the pharmaceutical composition according to this embodiment, the pharma-ceutically acceptable carrier may be an ingredient that does not inhibit the tumor lytic activity of the tumor lytic agent of the above embodiment and does not show substantial toxicity to the subject of administration.

[0058] Examples of pharma- ceutically acceptable carriers include excipients such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, and calcium carbonate; binders such as cellulose, methylcellulose, hydroxypropylcellulose, gelatin, gum arabic, polyethylene glycol, sucrose, and starch; disintegrants such as starch, carboxymethylcellulose, hydroxypropyl starch, sodium glycol-starch, sodium bicarbonate, calcium phosphate, and calcium citrate; lubricants such as magnesium stearate, aerosil, talc, and sodium lauryl sulfate; flavors such as citric acid, menthol, glycyrrhizin ammonium salt, glycine, and orange powder; preservatives such as sodium benzoate, sodium bisulfite, methylparaben, and propylparaben; stabilizers such as citric acid, sodium citrate, and acetic acid; suspending agents such as methylcellulose, polyvinylpyrrolidone, and aluminum stearate; dispersing agents such as surfactants; diluents such as water, buffer solutions, and physiological saline; and base waxes such as cacao butter, polyethylene glycol, and white kerosene.

[0059] When the pharmaceutical composition according to this embodiment is to be administered orally, the pharmaceutical composition formulation can be produced by a conventional method using additives commonly used for oral preparations, such as excipients, fillers, binders, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, solubilizing agents, antiseptics, flavoring agents, soothing agents, and stabilizers. Examples of usable additives include lactose, fructose, glucose, starch, gelatin, methylcellulose, gum arabic, polyethylene glycol, citric acid, sodium sulfite, sodium phosphate, β-cyclodextrin, and hydroxypropyl-β-cyclodextrin. When the pharmaceutical composition according to the present embodiment is to be administered orally, the pharmaceutical composition may be prepared in a dosage form suitable for oral administration, such as capsules, tablets, granules, powders, pills, fine granules, lozenges, etc.

[0060] When the pharmaceutical composition according to this embodiment is for parenteral administration, the pharmaceutical composition may contain an antioxidant, a buffer solution, a bacteriostatic agent, an isotonic agent, a suspending agent, a solubilizing agent, a thickening agent, a stabilizer, a preservative, and the like. When the pharmaceutical composition according to this embodiment is for parenteral administration, the pharmaceutical composition may be sealed in a container such as an ampoule, a vial, or a syringe cartridge in a unit dose or in multiple doses.

[0061] <Target diseases> The pharmaceutical composition of the present embodiment is used to treat tumors. Target tumors include those mentioned above in the embodiment relating to the tumor lytic agent, preferably solid malignant tumors, more preferably epithelial malignant tumors.

[0062] <Target of administration> The biological species to which the pharmaceutical composition of this embodiment is administered is not particularly limited as long as it is a subject capable of forming a tumor, and examples thereof include humans and non-human mammals, with humans being preferred. Examples of non-human mammals include rodents such as mice, rats, hamsters, and guinea pigs; lagomorphs such as rabbits; ungulates such as pigs, cows, goats, horses, and sheep; carnivores such as dogs and cats; and non-human primates such as monkeys, rhesus monkeys, cynomolgus monkeys, marmosets, orangutans, and chimpanzees.

[0063] <Administration Method> The method of administration of the pharmaceutical composition according to this embodiment is not particularly limited as long as the pharmaceutical composition exerts a therapeutic effect on the subject, and may be parenteral or oral administration, with parenteral administration being preferred.

[0064] Examples of parenteral administration include systemic administration such as intravenous administration and intra-arterial administration, and local administration such as intramuscular administration, subcutaneous administration, peritoneal administration, intraventricular administration, intrathecal administration, transdermal administration, intraocular administration, and intranasal administration. The pharmaceutical composition of this embodiment is preferably administered locally to the site where the cancer of the subject is present.

[0065] <Effective amount> The effective amount of the tumor lytic agent contained in the pharmaceutical composition according to this embodiment is not particularly limited as long as the pharmaceutical composition exerts a therapeutic effect, and can be appropriately determined by one skilled in the art.

[0066] <Dosage> The dosage of the pharmaceutical composition according to this embodiment is appropriately adjusted taking into consideration the age, sex, weight, symptoms, treatment method, administration method, treatment time, etc. of the subject to be administered. When the pharmaceutical composition according to this embodiment is administered orally, the dosage is appropriately determined, and may be, for example, about 0.1 to 2000 mg per patient to be treated, which may be administered once a day or in divided doses several times a day, or may be administered every few days.

[0067] The pharmaceutical composition according to the present embodiment described above is capable of destroying the solid form of a tumor by suppressing adhesion between tumor cells to be treated. The pharmaceutical composition according to the present embodiment is characterized by containing the above-mentioned tumor disintegrating agent. The above-mentioned tumor disintegrating agent contains compound (a0) or a salt thereof or a solvate thereof as an active ingredient. Compound (a0) has reduced cytotoxicity compared to the previously reported α-mannosidase inhibitor (Koyama R et al., Bioorganic & Medicinal Chemistry, June 2020, Vol. 28, no. 11, 115492.), and can induce tumor disintegration at a concentration lower than the cytotoxicity expression concentration range. Therefore, even if this pharmaceutical composition is administered to an individual to be treated, it is possible to reduce the side effects caused by this pharmaceutical composition in the individual.

[0068] When the treatment target is a solid malignant tumor, the pharmaceutical composition according to the present embodiment is preferably used in combination with an anticancer drug. The anticancer drug is not particularly limited as long as it is effective in treating cancer, and examples thereof include known anticancer drugs used in treating cancer. The known anticancer drug may be a low molecular weight drug, an antibody drug, or a cellular drug such as a chimeric antigen receptor T cell. The anticancer drug may be an anticancer drug that is normally used in the treatment of the solid malignant tumor, and may be appropriately selected according to the type of the solid malignant tumor to be treated. The dosage of the anticancer agent is not particularly limited as long as it is effective in treating cancer, and can be appropriately determined by a person skilled in the art.

[0069] When the pharmaceutical composition according to this embodiment is used in combination with an anticancer drug, the pharmaceutical composition may be administered to the subject before administering the anticancer drug, or the anticancer drug and the pharmaceutical composition may be administered to the subject at the same time. By allowing the pharmaceutical composition according to this embodiment to act on the cancer of the subject, the anticancer drug is easily delivered to the depth of the cancer, so that the dosage of the anticancer drug required for treatment can be reduced. As a result, the side effects of the anticancer drug in the subject can be reduced.

[0070] [Other embodiments] Other embodiments include, for example, methods of treating tumors comprising administering to a subject having a tumor in need of treatment an effective amount of an oncolytic agent of the above embodiments. In this embodiment, subjects to be treated include humans and non-human mammals. Tumor lytic agents include those mentioned above under [Tumor lytic agents]. The method for treating a tumor according to this embodiment may be a method for treating a solid malignant tumor, comprising administering an effective amount of the tumor lytic agent and the anticancer agent according to the above embodiment to a subject having a solid malignant tumor in need of treatment. In this embodiment, the effective amount may be the amount described above in [Pharmaceutical Composition], and can be appropriately determined by a person skilled in the art. The administration method of the tumor lytic agent may be the administration method described above in [Pharmaceutical Composition].

[0071] Other embodiments include, for example, the use of the oncolytic agent of the above embodiments for the manufacture of a pharmaceutical composition for treating tumors. Tumor lytic agents include those mentioned above under [Tumor lytic agents]. EXAMPLES

[0072] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.

[0073] <Production examples of compounds> First, the following compounds pre1 to pre4 were synthesized using piperonal as a raw material according to the following procedure. Compound pre1: Ethyl 3-(1,3-benzodioxol-5-yl)-2-cyano-2-propenoate Compound pre2: Ethyl α-cyano-β-(4-methoxyphenyl)-1,3-benzodioxole-5-propanoate Compound pre3: α-Cyano-β-(4-methoxyphenyl)-1,3-benzodioxole-5-propanoicacid Compound pre4: β-(4-Methoxyphenyl)-1,3-benzodioxole-5-propanenitrile

[0074] [ka]

[0075] Piperonal (Wako, 165-02782, 3.00 g, 19.99 mmol) was dissolved in dehydrated toluene (Wako, 202-17911, 100 mL) in a nitrogen atmosphere, and ethyl cyanoacetate (TCI, C0441, 2.3 mL, 20.99 mmol) and piperidine (TCI, P0453, 200 μL, 1.99 mmol) were added in that order, and the mixture was heated and refluxed in an oil bath at 140 ° C for 1 hour and 30 minutes. The solvent was then distilled off and the mixture was dried in vacuum. 5 mL of 99.5% ethanol was added to the obtained reaction product, which was then subjected to thermal recrystallization, and the compound pre1 (4.55 g, yield 92.8%) was obtained as a yellow crystal by Kiriyama filtration.

[0076] Compound pre1 (2.22 g, 9.04 mmol) was dissolved in dehydrated toluene (45 mL) under a nitrogen atmosphere, and 0.5 M 4-methoxyphenylmagnesium bromide THF solution (Sigma-Aldrich, 470260-100ML, 28 mL, 13.56 mmol) was added and stirred at room temperature for 15 minutes. 16 mL of 1.2 M hydrochloric acid was added to the reaction solution to stop the reaction. The solution after the reaction was stopped was added to a separatory funnel containing 70 mL of diethyl ether and 70 mL of 1.2 M hydrochloric acid, and the product was extracted. The obtained organic layer was washed with 70 mL of saturated saline and then dried with anhydrous sodium sulfate. The solvent was distilled off, and then vacuum dried. The obtained residue was purified by silica gel column chromatography (developing solvent: toluene / ethyl acetate = 15 / 1) to quantitatively obtain compound pre2 (3.31 g).

[0077] Compound pre2 (3.31 g, 9.37 mmol) was dissolved in special grade methanol (Wako, 131-01826, 164 mL), 33 mL of pure water, and 28% sodium methoxide methanol solution (Wako, 197-02463, 4 mL) were added in that order, and the mixture was stirred at room temperature for 1 hour and 40 minutes. Then, DOWEX50W-X8 (Wako, 328-97585, H+ form) was added and stirred to neutralize. The pH of the reaction solution was confirmed to be pH 7 by pH test paper. Then, DOWEX50W-X8 was removed by cotton plug filtration, the solvent was distilled off, and the mixture was dried in vacuum. The resulting residue was purified by silica gel column chromatography (developing solvent: dichloromethane / methanol / trifluoroacetic acid = 8 / 1 / 0.1) to obtain compound pre3 (2.83 g, yield 92.9%).

[0078] Compound pre3 (2.45 g, 7.52 mmol) was dissolved in N,N-dimethylacetamide (DMA, Wako, 042-02541, 20 mL) and heated to reflux in a 140 ° C oil bath for 2 hours. The reaction solution was added to a separatory funnel containing 400 mL of diethyl ether and 400 mL of pure water, and the product was extracted. The resulting organic layer was washed with 400 mL of saturated saline and then dried with anhydrous sodium sulfate. The solvent was distilled off and then vacuum dried, and the resulting residue was purified by silica gel column chromatography (developing solvent: hexane / ethyl acetate = 5 / 2) to obtain compound pre4 (1.80 g, yield 80.2%).

[0079] [Production Example 1: Production of compound (a1-1)] Compound pre4 (146.3 mg, 0.518 mmol) was dissolved in dehydrated tetrahydrofuran (THF, Wako, 205-17901, 10 mL) under a nitrogen atmosphere, lithium aluminum hydride (Wako, 120-01091, 51.0 mg, 1.036 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Then, 11 drops of saturated anhydrous sodium sulfate aqueous solution were added with a Pasteur pipette, and the mixture was filtered through Celite. The solvent of the filtrate was removed by a rotary evaporator and dried in vacuum. The entire amount of the obtained product was dissolved in dehydrated dichloromethane (Wako, 042-31231, 10 mL), N,N-diisopropylethylamine (DIEA, TCI, D1599, 270 μL, 1.554 mmol) and benzene sulfonyl chloride (Sigma-Aldrich, 108138-5G, 100 μL, 0.777 mmol) were added, and the mixture was stirred at room temperature for 1 hour and 30 minutes. After that, the solvent was removed using a rotary evaporator, and the resulting residue was purified by silica gel column chromatography (developing solvent: hexane / ethyl acetate = 5 / 3). The obtained product was again subjected to silica gel column chromatography (developing solvent: toluene / ethyl acetate = 8 / 1) to obtain compound (a1-1) (114.1 mg, yield 51.8%).

[0080] [ka]

[0081] 1 H-NMR, 13 The results of measurements of compound (a1-1) by C-NMR, DUIS-MS, and HRMS are shown below. In this specification, DUIS-MS stands for Dual Ion Source Mass Spectrometry, and HRMS stands for High Resolution Mass Spectrometry.

[0082] 1H-NMR(500MHz,CDCl3):δ2.12(ddd,2H,J=2.0,8.3and14.8Hz,-CHCH2CH2N-),2.89(dd,2H,J=7.0and13.0Hz,-CHCH2CH2N-),3.76(s,3H,-OCH3),3.80(td,1H,J=7.5Hz,-CHCH2CH2N-),4.29(t,1H,J=6.3Hz,-CHCH2CH2NH-),5.89(dd,2H,J=1.5and2.0Hz,-OCH2O-),6.59(dd,1H,J=1.5Hz,H2inpiperonylgroup),6.59(dd,1H,J=1.5and8.0Hz,H6inpiperonylgroup),6.68(d,1H,J=8.0Hz,H5inpiperonylgroup),6.79(dd,2H,J=2.5and8.5Hz,H3andH5in4-methoxyphenylgroup),7.03(ddd,2H,J=2.8and9.0Hz,H2andH6in4-methoxyphenylgroup),6.94(ddd,2H,J=1.8,3.0and9.5Hz,H3andH5inphenylgroup),7.58(td,1H,J=1.0and8.0Hz,H4inphenylgroup),7.72(ddd,2H,J=2.5and9.5Hz,H2andH6inphenylgroup).

[0083] 13C-NMR(125MHz,CDCl3):δ35.60(-CHCH2CH2N-),41.65(-CHCH2CH2N-),47.02(-CHCH2CH2N-),55.24(-OCH3),100.92 (-OCH2O-),107.96(C2inpiperonylgroup),108.19(C5inpiperonylgroup),114.00(C3andC5in4-methoxyphenylgr oup),120.49(C6inpiperonylgroup),114.21(C3andC5inphenylgroup),128.43(C2andC6in4-methoxyphenylgroup ),129.24(C2andC6inphenylgroup),132.65(C4inphenylgroup),135.76,137.96,139.78,146.01,147.81,158.12.

[0084] DUIS-MS:(positivemode);m / z=448[M+Na]+,(negativemode);424[MH]-. HRMS:(ESInegative);m / zcalc'dforC23H22NO5S[MH]-:424.1224,found:424.1221(error0.71ppm).

[0085] [Production Example 2: Production of compound (a1-2)] Compound (a1-2) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to 4-chlorobenzenesulfonyl chloride.

[0086] [ka]

[0087] 1 H-NMR, 13 The measurement results of compound (a1-2) by C-NMR, DUIS-MS, and HRMS are shown below.

[0088] 1 H-NMR(500MHz,CDCl3):δ2.13(ddd,2H,J=1.5,7.0and15.0Hz,-CHCH2CH2N-),2.92(dd,2H,J=6.8and13.3Hz,-CHCH2CH2N-),3.78(s,3H,-OCH3),3.79(td,1H,J=8.3Hz,-CHCH2CH2N-),4.40(t,1H,J=6.3Hz,-CHCH2CH2NH-),5.90(d,2H,J=3.3Hz,-OCH2O-),6.58(s,1H,H2inpiperonylgroup),6.59(dd,1H,J=1.5Hzand8.0Hz,H6inpiperonylgroup),6.69(d,1H,J=8.0Hz,H5inpiperonylgroup),6.80(d,2H,J=8.5Hz,H3andH5in4-methoxyphenylgroup),7.03(d,2H,J=8.5Hz,H2andH6in4-methoxyphenylgroup),7.46(d,2H,J=8.5Hz,H3andH5in4-chlorophenylgroup),7.71(d,2H,J=7.0Hz,H2andH6in4-chlorophenylgroup).

[0089] 13 C-NMR(125MHz,CDCl3):δ35.59(-CHCH2CH2NH-),41.75(-CHCH2CH2NH-),47.02(-CHCH2CH2NH-),55.26(-OCH3),100.96(-OCH2O-),107.90(C2-inpiperonylgroup),108.24(C5inpiperonylgroup),114.05(C3andC5in4-methoxyphenylgroup),120.44(C6inpiperonylgroup),128.40(C2andC6in4-methoxyphenylgroup),128.54(C2andC6in4-chlorophenylgroup),129.39(C3andC5in4-chlorophenylgroup),135.65,137.87,138.32,139.16,146.08,147.86,158.19.

[0090] DUIS-MS:(positivemode);m / z=482[M+Na]+,(negativemode);458[MH]-. HRMS:(ESInegative);m / zcalc'dforC23H21ClNO5S[MH]-:458.0834,found:458.0832(error0.44ppm).

[0091] [Production Example 3: Production of compound (a1-3)] Compound (a1-3) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to 4-methoxybenzenesulfonyl chloride.

[0092] [ka]

[0093] 1 H-NMR, 13 The measurement results of compound (a1-3) by C-NMR, DUIS-MS, and HRMS are shown below.

[0094] 1<h2 style=";text-align:left;direction:ltr">H-NMR (500MHz,CDCl3): δ2.12(ddd,2H,J=2.0,8.3,and14.8Hz,-CHCH2CH2N-), 2.89(dd,2H,J=7.0and13.0Hz,-CHCH2CH2N-), 3.76(s,3H,>CH(C6H4)OCH3), 3.80(td,1H,J=7.5Hz,-CHCH2CH2N-), 3.87(s,3H,-SO2(C6H4)OCH3), 4.29(t,1H,J=6.3Hz,-CHCH2CH2NH-), 5.89(dd,2H,J=1.5and2.0Hz,-OCH2O-), 6.57(d,1H,J=1.5Hz,H2inpiperonylgro up), 6.59(d,1H,J=1.5 and 8.0Hz,H6inpiperonylgroup), 6.68(d,1H,J=8.0Hz,H5inpiperonylgroup), 6.79(ddd,2H,J=2.5 and 8.5Hz,H3andH5of>CH(C6H4)OCH3), 7.03(ddd,2H,J=2.8 and 9.0Hz,H2andH6of>CH(C6H4)OCH3), 6.94(ddd,2H,J=1.8,3.0 and 9.5Hz,H3andH5-SO2(C6H4)OCH3), 7.72(ddd,2H,J=2.5 and 9.0Hz,H2andH6-SO2(C6H4)OCH3).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0095] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 13C-NMR(125MHz,CDCl3):δ35.60(-CHCH2CH2N-),41.65(-CHCH2CH2N-),47.02(-CHCH2CH2N-),55.24(>CH(C6H4)OCH3) ,55.60(-SO2(C6H4)OCH3),100.92(-OCH2O-),107.96(C2inpiperonylgroup),108.19(C5inpiperonylgroup),114.0 0(C3andC5of>CH(C6H4)OCH3),114.21,(C3andC5,-SO2(C6H4)OCH3),120.49(C6inpiperonylgroup),128.43(C2andC 6of>CH(C6H4)OCH3),129.24(C2andC6,-SO2(C6H4)OCH3),131.37,135.84,138.04,146.00,147.82,158.14,162.87.

[0096] DUIS-MS:(positivemode);m / z=478[M+Na]+,(negativemode);454[MH]-. HRMS:(ESInegative);m / zcalc'dforC24H24NO6S[MH]-:454.1330,found:454.1328(error0.44ppm).

[0097] [Production Example 4: Production of compound (a1-4)] Compound (a1-4) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to p-toluenesulfonyl chloride.

[0098] [ka]

[0099] 1 H-NMR, 13 The measurement results of compound (a1-4) by C-NMR, DUIS-MS, and HRMS are shown below.

[0100] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H-NMR (500MHz,CDCl3): δ2.12(dd,2H,J=6.8 and 14.3Hz,-CHCH2CH2N-), 2.42(s,3H,CH3), 2.90(dd,2H,J=6.5 and 13.5Hz,-CHCH2CH2N-), 3.76(s,3H,-OCH3), 3.80(td,1H,J=7.5Hz,-CHCH2CH2N-), 4.35(t,1H,J=6.0Hz,-CHCH2CH2NH-), 5.89(s,2H,-OCH2O-), 6.56(d,1H,J=1.5Hz,H2inpiperonylgroup), 6.5 9(dd,1H,J=1.0and9.0Hz,H6inpiperonylgroup),6.68(d,1H,J=8.0Hz,H5inpiperonylgroup),6.79(d,2H,J=8.5Hz,H3andH5in4-methoxyphenylgroup) ,7.03(d,2H,J=8.5Hz,H2andH6in4-methoxyphenylgroup),7.28(d,2H,J=7.5Hz,H3andH5intolylgroup),7.67(d,2H,J=8.0Hz,H2andH6intolylgroup).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0101] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C-NMR(125MHz,CDCl3):δ21.52(-CH3),35.65(-CHCH2CH2N-),41.70(-CHCH2CH2N-),47.01(-CHCH2CH2N-),55.24 (-OCH3),100.92(-OCH2O-),107.96(C2inpiperonylgroup),108.19(C5inpiperonylgroup),114.00(C3andC5in4 -methoxyphenylgroup),120.49(C6inpiperonylgroup),127.12(C2andC6intolylgroup),128.44(C2andC6in4-m ethoxyphenylgroup),129.69(C3andC5intolylgroup),135.83,136.87,138.05,143.43,146.00,147.82,158.15.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0102] <h2 style=";text-align:left;direction:ltr"> DUIS-MS:(positivemode);m / z=462[M+Na]+,(negativemode);438[MH]-. HRMS:(ESInegative);m / zcalc'dforC24H24NO5S[MH]-:438.13807,found:438.13785(error0.50ppm).

[0103] [Production Example 5: Production of compound (a1-5)] (a1-5) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to 3,4-dichlorobenzenesulfonyl chloride.

[0104] [ka]

[0105] 1 H-NMR, 13 The measurement results of compound (a1-5) by C-NMR, DUIS-MS, and HRMS are shown below.

[0106] 1H-NMR(500MHz,CDCl3):δ2.16(ddd,2H,J=1.3,7.3and14.8Hz,-CHCH2CH2N-),2.94(dd,2H,J=6.0and13.0Hz,-CHCH2CH2N-),3.77(s,3H,-OCH3),3.80(td,1H,J=8.0Hz,-CHCH2CH2N-),4.41(t,1H,J=6.0Hz,-CHCH2CH2NH-),5.91(d,2H,J=1.0Hz,-OCH2O-),6.59(d,1H,J=1.5Hz,H2inpiperonylgroup),6.60(dd,1H,J=1.5and8.0Hz,H6inpiperonylgroup),6.70(d,1H,J=8.5Hz,H5inpiperonylgroup),6.81(ddd,2H,J=2.6and8.5Hz,H3andH5in4-methoxyphenylgroup),7.04(ddd,2H,J=2.6and9.0Hz,H2andH6in4-methoxyphenylgroup),7.56(d,1H,J=8.5Hz,H5in3,4-dichlorophenylgroup),7.60(dd,1H,J=1.8and8.3Hz,H6in3,4-dichlorophenylgroup),7.87(d,1H,J=1.5Hz,H2in3,4-dichlorophenylgroup).

[0107] 13C-NMR(125MHz,CDCl3):δ35.56(-CHCH2CH2N-),41.85(-CHCH2CH2N-),47.04(-CHCH2CH2N-),55.26(-OCH3),100.99(-OCH2O-), 107.86(C2inpiperonylgroup),108.27(C5inpiperonylgroup),114.09(C3andC5in4-methoxyphenylgroup),120.40(C6inpipe ronylgroup),126.13(C2in3,4-dichlorophenylgroup),128.37(C2andC6in4-methoxyphenylgroup),129.06(C6in3,4-dichlo rophenylgroup),131.14(C5in3,4-dichlorophenylgroup),133.75,135.53,137.50,137.78,139.62,146.13,147.90,158.24.

[0108] DUIS-MS:(positivemode);m / z=516[M+Na]+,(negativemode);492[MH]-. HRMS:(ESInegative);m / zcalc'dforC23H20Cl2NO5S[MH]-:492.04447,found:492.04425(error0.45ppm).

[0109] [Production Example 6: Production of compound (a1-6)] (a1-6) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to 4-(trifluoromethyl)benzenesulfonyl chloride.

[0110] [ka]

[0111] 1 H-NMR, 13The measurement results of compound (a1-6) by 13C-NMR, DUIS-MS, and HRMS are shown below.

[0112] 1 1H-NMR (500 MHz, CDCl3): δ 2.15 (dd, 2H, J = 2.0, 7.3, and 15.3 Hz, -CHCH2CH2N-), 2.96 (dd, 2H, J = 7.0 and 13.0 Hz, -CHCH2CH2N-), 3.77 (s, 3H, -OCH3), 3.79 (dd, 1H, J = 8.5 Hz, -CHCH2CH2N-), 4.45 (t, 1H, J = 6.3 Hz, -CHCH2CH2NH-), 5.90 (dd, 2H, J = 1.3 and 2.8 Hz, -OCH2O-), 6.58 (d, 1H, J = 1.5 Hz, H2 in piperonyl group), 6.59 (dd, 1H, J = 2.5 and 8.0 Hz, H6 in piperonyl group), 6.69 (d, 1H, J = 8.0 Hz, H5 in piperonyl group), 6.80 (ddd, 2H, J = 2.5 and 8.5 Hz, H3 and H5 in 4-methoxyphenyl group), 7.03 (dd, 2H, J = 2.0 and 8.5 Hz, H2 and H4 in 4-methoxyphenyl group), 7.91 (d, 2H, J = 8.0 Hz, H3 and H5 in 4-trifluoromethylphenyl group), 7.76 (d, 2H, J = 8.5 Hz, H2 and H6 in 4-trifluoromethylphenyl group).

[0113] 13C-NMR (125MHz, CDCl3): δ35.64(-CHCH2CH2N-),41.85(-CHCH2CH2N-),47.03(-CHCH2CH2N-),55.25(-OCH3),100.97(-OCH2O-),107.87(C2inpiper onylgroup),108.25(C5inpiperonylgroup),114.07(C3andC5in4-methoxyphenylgroup),120.41(C6inpiperonylgroup),123.21(d,1C,J=270.6Hz ),C4in4-trifluoromethylphenylgroup),126.28(d,J=3.6Hz,C3andC5in4-trifluoromethylphenylgroup),127.57(C6in4-trifluoromethylphe nylgroup),128.37(C2andC6in4-methoxyphenylgroup),134.37(q,1C,J=33.0Hz,-(C6H4)CF3),135.57,1317.78,143.47,146.13,147.89,158.23.

[0114] DUIS-MS:(positivemode);m / z=516[M+Na]+,(negativemode);492[MH]-. HRMS:(ESInegative);m / zcalc'dforC24H21F3NO5S[MH]-:492.1098,found:492.1095(error0.61ppm).

[0115] [Production Example 7: Production of compound (a1-7)] (a1-7) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to 4-nitrobenzenesulfonyl chloride.

[0116] [ka]

[0117] 1H-NMR(500MHz,CDCl3):δ2.16(ddd,2H,J=2.1,6.9,and14.5Hz,-CHCH2CH2N-),2.98(dd,2H,J=6.8and13.3Hz,-CHCH2CH2N-),3.77(s,3H,-OCH3),3.79(td,1H,J=8.3and16.3Hz,-CHCH2CH2N-),4.56(t,1H,J=6.0Hz,-CHCH2CH2NH-),5.90(dd,2H,J=1.8and3.3Hz,-OCH2O-),6.54(d,1H,J=1.5Hz,H2inpiperonylgroup),6.60(dd,1H,J=1.5and8.0Hz,H6inpiperonylgroup),6.69(d,1H,J=8.0Hz,H5inpiperonylgroup),6.80(dd,2H,J=2.0and9.0Hz,H3andH5in4-methoxyphenylgroup),7.03(ddd,2H,J=3.3and8.5Hz,H2andH6in4-methoxyphenylgroup),7.32(ddd,2H,J=2.2and9.3Hz,H3andH5in4-nitrophenylgroup),7.96(ddd,2H,J=2.0and9.0Hz,H2andH6in4-nitrophenylgroup).

[0118] 13C-NMR (125MHz, CDCl3): δ35.53(-CHCH2CH2N-),41.85(-CHCH2CH2N-),46.94(-CHCH2CH2N-),55.25(-OCH3),101.0 1(-OCH2O-),107.79(C2inpiperonylgroup),108.27(C5inpiperonylgroup),114.03(C3andC5in4-methoxyphenyl group),120.35(C6inpiperonylgroup),124.37(C3andC5in4-nitrophenylgroup),128.27(C2andC6in4-nitrophe nylgroup),128.32(C2andC6in4-methoxyphenylgroup),135.44,137.60,145.56,146.11,147.85,149.96,158.20.

[0119] DUIS-MS:(negativemode);m / z=469[MH]-. HRMS:(ESInegative);m / zcalc'dforC23H21N2O7S[MH]-:469.1075,found:469.1072(error0.64ppm).

[0120] [Production Example 8: Production of compound (a1-8)] Compound (a1-8) was synthesized in the same manner as in Production Example 1, except that benzenesulfonyl chloride was changed to 4-chloro-3-(trifluoromethyl)benzenesulfonyl chloride.

[0121] [ka]

[0122] 1 H-NMR, 13 The measurement results for compound (a1-8) by C-NMR, DUIS-MS, and HRMS are shown below.

[0123] 1 H-NMR(500MHz,CDCl3):δ2.17(dd,2H,J=7.0and13.5Hz,-CHCH2CH2N-),2.94(dd,2H,J=6.3and13.8Hz,-CHCH2CH2N-),3.77(s,3H,-OCH3),3.80(dd,1H,J=8.0Hz,-CHCH2CH2N-),4.55(t,1H,J=6.0Hz,-CHCH2CH2NH-),5.91(d,2H,J=1.0Hz,-OCH2O-),6.59(s,1H),6.61(dd,1H,J=1.5and8.0Hz,H6inpiperonylgroup),6.70(d,1H,J=8.0Hz,H5inpiperonylgroup),6.80(ddd,2H,J=2.5and9.5Hz,H3andH5in4-methoxyphenylgroup),7.04(ddd,2H,J=2.8and8.8Hz,H2andH6in4-methoxyphenylgroup),7.63(d,1H,J=8.0Hz,H5in3-Chloro-4-trifluoromethylphenylgroup),7.87(dd,1H,J=2.0and8.0Hz,H6in3-Chloro-4-trifluoromethylphenylgroup),8.11(d,1H,J=1.5Hz,H2in3-Chloro-4-trifluoromethylphenylgroup).

[0124] 1313C-NMR (125 MHz, CDCl3): δ 35.52 (-CHCH2CH2N-), 41.86 (-CHCH2CH2N-), 46.97 (-CHCH2CH2N-), 55.23 (-OCH3), 100.99 (-OCH2O-), 107.80 (C2 in piperonyl group), 108.25 (C5 in piperonyl group), 114.03 (C3 and C5 in 4-methoxyphenyl group), 120.35 (C6 in piperonyl group), 121.94 (d, 1C, J = 271.8 Hz, -CF3), 126.39 (d, J = 5.9 Hz, C2 in 3-Chloro-4-trifluoromethylphenyl group) 126.47 (d, J = 4.8 Hz, C3 in 3-Chloro-4-trifluoromethylphenyl group), 128.33 (C2 and C6 in 4-methoxyphenyl group), 129.31 (q, J = 32.3 Hz, C4 in 3-Chloro-4-trifluoromethylphenyl group), 131.26 (C6 in 3-Chloro-4-trifluoromethylphenyl group), 132.41 (C5 in 3-Chloro-4-trifluoromethylphenyl group), 131.26, 135.44, 137.70, 139.05, 158.19.

[0125] DUIS-MS: (positive mode); m / z = 550 [M+Na]+, (negative mode); 526 [M-H]-. HRMS: (ESI negative); m / z calc’d for C24H20ClF3NO5S [M-H]-: 526.0708, found: 526.0706 (error 0.38 ppm).

[0126] [Compound of Comparative Example] Compound (b-1) was prepared as a comparative compound. Compound (b-1) is AR525 reported as an α-mannosidase inhibitor in Koyama R et al. (Bioorganic & Medicinal Chemistry, June 2020, Vol. 28, no. 11, 115492). AR525 is a compound that showed high α-mannosidase inhibitory activity among the compounds reported as α-mannosidase inhibitors in Koyama R et al.

[0127] [ka]

[0128] Materials and Methods In the experimental examples, the following cells and reagents were used. OVCAR-3 (RIKEN Cell Bank Cell No. RCB2135) was used as a human ovarian cancer-derived cell line. Fetal Bovine Serum South (FBS, BioWest, S1810-500) was used as fetal bovine serum for cell culture. As an antibiotic, a penicillin-streptomycin solution (x100) (Fujifilm Wako Pure Chemical Industries, Ltd. (hereinafter, Wako), 168-23191) was used. Antibiotic-free 10% FBS RPMI1640 medium was prepared by adding FBS to RPMI1640 medium (Sigma-Aldrich, 500 mL, R8758). Antibiotic-containing 10% FBS RPMI1640 medium was prepared by adding penicillin-streptomycin solution (×100) to RPMI1640 medium (Sigma-Aldrich, 500 mL, R8758). The final concentrations of antibiotics in the obtained medium were 100 units / mL for penicillin G and 100 μg / mL for streptomycin sulfate. The cell detachment solution (PET) was prepared by adding 0.5 w / v% Trypsin-5.3 mmol / l EDTA·4Na Solution without Phenol Red (× 10) (Wako, 208-17251) to 1× PBS.

[0129] The cell density was measured by the method described below. 10 μL of the cell suspension was taken and mixed with 10 μL of trypan blue cell stain (Trypan Blue Stain (0.4%) for use with the CountessTM Automated Cell Counter, Thermo Fisher Scientific, T10282) on parafilm, after which 10 μL was taken and placed on a cell counting slide (CountessTM cell counting chamber slides, Thermo Fisher Scientific, C10283), and the cell number and cell viability were confirmed using a CountessTMII automated cell counter, Thermo Fisher Scientific, AMQAX1000.

[0130] [Experimental Example 1] (Cytotoxicity evaluation) According to the procedure shown below, the cytotoxicity of compounds (a1-1) to (a1-8) and compound (b-1) was evaluated using monolayer cultured human ovarian cancer-derived cells (OVCAR-3 cells).

[0131] Compounds (a1-1) to (a1-8) (each at 5 mM) and compound (b-1) (5 mM) were prepared using DMSO. Then, OVCAR-3 cells were seeded on a 96-well plate by the following procedure.

[0132] OVCAR-3 cells, 25 cm 2 The cells were cultured in a 25cm flask for 7 days. 2The antibiotic-containing 10% FBS RPMI1640 medium was removed from the flask using an aspirator, and the flask was washed three times with 2 mL of PBS(-) warmed to 37°C. 2 mL of PET warmed to 37°C was added thereto, left to stand for 5 minutes, and gently shaken to detach the cells. 2 mL of antibiotic-free 10% FBS RPMI1640 medium was added to the obtained liquid to inactivate the trypsin in the PET. 4 mL of the obtained liquid was transferred to a 15 mL tube and centrifuged at 3,000 rpm and 25°C for 5 minutes (using a soft brake). The supernatant was then removed, and 1 mL of antibiotic-free RPMI1640 medium was added and suspended to obtain a cell suspension. The cell density (cells / mL) of the obtained cell suspension was measured by counting, and the cell density was adjusted. OVCAR-3 cells were added to each well of a 96-well plate (CORNING, 353072) at a concentration of 1.0 × 10 4 The cell suspension (100 μL) was added so that each well of the 96-well plate was 1. The 96-well plate was then transferred into a CO incubator and cultured at 37° C. and 5% CO for 24 hours.

[0133] The prepared compounds (a1-1) to (a1-8) (5 mM each) and compound (b-1) (5 mM) were diluted with antibiotic-free 10% FBS RPMI1640 medium. At this time, the final concentration of KIF was 10 μM, and the final concentrations of compounds (a1-1) to (a1-8) and compound (b-1) were each 50 μM. Next, the medium in each well of the 96-well plate was removed with an aspirator, and then 100 μL of the diluted solutions of compounds (a1-1) to (a1-8) and compound (b-1) were added to each well.

[0134] Next, cytotoxicity was evaluated according to the following procedure based on the WST-8 method for measuring cellular respiration: Cell Counting Kit-8 (CCK-8, Wako, 343-07623) was used for cytotoxicity evaluation. The 96-well plate was transferred to a CO2 incubator and incubated at 37°C and 5% CO2 for 24 hours, after which 10 μL of CCK-8 solution was added to each well. The plate was transferred to a CO2 incubator and incubated at 37°C and 5% CO2 for 2 hours. The absorbance at 450 nm was measured using a microplate reader (iMark, 2009-231-0000496) with the absorbance at 650 nm as the reference wavelength. The cell viability was calculated based on the absorbance measurements to evaluate cytotoxicity. The results are shown in Table 1.

[0135] [Table 1]

[0136] The cell viability after exposure of the cells to compound (b-1) was 1.2%. The cell viability after exposure of the cells to compounds (a1-1) to (a1-8) for 24 hours was 52 to 100%. It was confirmed that compounds (a1-1) to (a1-8) have significantly lower cytotoxicity than compound (b-1).

[0137] [Experimental Example 2] (GM inhibitory activity evaluation) According to the following procedure, the localization of HM-type glycans in cells was observed using fluorescently labeled concanavalin (Con-A) and fluorescently labeled snowdrop lectin (SDL) in cells contacted with GMII inhibitors kifunensine (KIF) and deoxymannojirimycin (DMJ), GMII inhibitors swainsonine (SWA) and mannostatin (ManA), and compounds (a1-1) to (a1-8).

[0138] Concanavalin A Alexa Fluor 488 conjugate (Con-A, Life Technologies, C11252) was dissolved in PBS to obtain a Con-A Alexa Fluor 488 solution (25 μg / mL). 5 mg / mL SDL FITC solution (Vector Laboratories, FL-1181) was diluted with PBS to obtain a SDL FITC solution (25 μg / mL).

[0139] OVCAR-3 cells, 75 cm 2 The cells were cultured for 3-4 days in a flask. The medium was removed from the flask and the flask was washed three times with 6 mL of 1x PBS(-) warmed to 37°C. The cells were quickly detached with 6 mL of PET warmed to 37°C. 6 mL of antibiotic-free RPMI medium warmed to 37°C was added. The cell suspension was transferred to a 15 mL tube and centrifuged (room temperature, 3000 rpm, 5 min). The supernatant was removed and the cells were suspended in 1 mL of antibiotic-free RPMI medium warmed to 37°C. The number of live cells in the suspension was measured using a Countess and the cell density was adjusted. A polylysine-coated cover glass (Matsunami Glass Industry Co., Ltd., C1210) was placed in each well of a 6-well plate (SigmaAldrich, SIAL0516). Then, OVCAR-3 cells were placed in each well of the 6-well plate at a density of 9.0 × 10 4 1 mL of the cell suspension was added to each well so that the number of cells was 1. The 6-well plate was then cultured in a CO2 incubator for 72 hours.

[0140] After 72 hours of culture, the medium in the wells of the 6-well plate was removed with an aspirator, and 1 mL of antibiotic-free medium warmed to 37°C was added to each well. KIF, DMJ, SWA, or ManA solution was added to each well so that the final concentration was 100 μM. Compounds (a1-1) to (a1-8) were added to each well so that the final concentration was 25 μM.

[0141] After culturing for 72 hours in a CO2 incubator, the medium in the wells was removed with an aspirator and washed with PBS. The cover glass of all wells was transferred, with the cell-cultured side facing up, to six flat petri dishes (ASONE, 1-4564-01, FS-30, φ32×15mm) containing 1mL of PBS. 1mL of methanol (Wako, 131-01826)-acetone (Wako, 016-00346) (1:1) mixture cooled to -20℃ was added to the petri dishes and left to stand at -20℃ for 20 minutes. The methanol-acetone mixture in the petri dishes was removed with a Pasteur pipette and then washed with PBS.

[0142] 1 mL each of 25 μg / mL ConA AlexaFluor488 solution or 25 μg / mL SDL FITC was added to the dish and left to stand at room temperature for 15 minutes. Then, each solution in the dish was removed with an aspirator, and the dish was washed with PBS.

[0143] The cover glass was placed with the cell-seeded side facing down on a slide glass (Matsunami Glass Industry Co., Ltd., S0317) on which one drop of mounting medium (ibidi Mounting Medium, No. 50001) had been applied, and the cover glass was fixed onto the slide glass using a hard top coat (Kouji Honpo, Nail List, JAN: 4972915068290) and air-dried for 5 minutes.

[0144] The obtained fluorescently stained cells were observed using a confocal laser microscope (TCS SP8 LIGHTNING, Leica). The results are shown in Figures 1 and 2.

[0145] Con-A staining of DMSO-treated cells, which is a negative control, stained the Golgi apparatus, and SDL staining of DMSO-treated cells faintly stained the Golgi apparatus.

[0146] Con-A staining of cells treated with KIF and DMJ, which are GMI inhibitors, stained the cytoplasm and cell surface of the whole cell in addition to the Golgi apparatus, whereas SDL staining of cells treated with KIF and DMJ showed granular staining of the Golgi apparatus.

[0147] Con-A staining of cells treated with GMII inhibitors SWA and ManA revealed granular staining around the nucleus, and staining of the entire cell in the cytoplasm and cell surface. In SDL staining of SWA- and ManA-treated cells, staining with a granular appearance was confirmed not only in the Golgi apparatus but also throughout the cell, including the cytoplasm.

[0148] In the Con-A staining of cells contacted with any of the compounds (a1-1) to (a1-8), the entire cell, including the cytoplasm and cell surface, was stained in addition to the Golgi apparatus, as with known GMI inhibitors. This result suggests that the compounds (a1-1) to (a1-8) inhibit GMI. In SDL staining of cells contacted with any of the compounds (a1-1) to (a1-8), staining was observed over a wider area than when known GMII inhibitors were used, or staining similar to that when GMII inhibitors were used was observed. This result suggests that the compounds (a1-1) to (a1-8) inhibit GMII.

[0149] [Experimental Example 3] (Spheroid disruption activity evaluation) According to the procedure shown below, the spheroid (SPH) disruption activity of GMII inhibitors KIF and DMJ, GMII inhibitors SWA and ManA, and compounds (a1-1) to (a1-8) was evaluated.

[0150] First, KIF (2 mM), DMJ (20 mM), SWA (20 mM), ManA (20 mM), and compounds (a1-1) to (a1-8) (each at 5 mM) were prepared using DMSO. Next, an agarose-added plate was prepared according to the following procedure. 60 mg of agarose (Lonza Co., Ltd., 50071) was weighed onto a packing paper, added to a 50 mL tube in a safety cabinet, and 8 mL of PBS (-) was added. The 50 mL tube was placed in a 250 mL beaker containing water, heated in a microwave oven for 10 seconds, removed and stirred, and this procedure was repeated until the agarose dissolved in PBS and became transparent, producing a 0.75% (w / v) agarose solution. The solution was dispensed into a reservoir in a safety cabinet, and 50 μL was added to a 96-well plate using an 8-channel pipette, and left to stand until the agarose solidified.

[0151] OVCAR-3 cells, 25 cm 2 or 75cm 2 The cells were cultured in a 25cm flask for 7 days. 2 or 75cm 2 The antibiotic-containing 10% FBS RPMI1640 medium was removed from the flask with an aspirator, and the flask was washed three times with 2 mL or 6 mL of PBS(-) warmed to 37°C. 2 mL or 6 mL of PET warmed to 37°C was added thereto, left to stand for 5 minutes, and gently shaken to detach the cells. 2 mL or 6 mL of antibiotic-free 10% FBS RPMI1640 medium was added to the obtained liquid to inactivate the trypsin in the PET. 4 mL or 12 mL of the obtained liquid was transferred to a 15 mL tube in its entirety and centrifuged at 3,000 rpm and 25°C for 5 minutes. The supernatant was then removed, and 1 mL of antibiotic-free RPMI1640 medium was added and suspended to prepare a cell suspension. The cell density (cells / mL) of the obtained cell suspension was measured by counting, and the cell density was adjusted. OVCAR-3 cells were placed in each well of a 96-well plate (CORNING, 353072) at 5.0 × 10 per well. 3 A cell suspension was prepared in a 15 mL tube so that each cell would contain one cell.

[0152] 4.5μL of each of the prepared KIF (2mM), DMJ (20mM), SWA (20mM), ManA (20mM), compounds (a1-1) to (a1-8) (each 5mM), and DMSO (negative control) were taken and added to 900μL of the cell suspension, and the mixture was mixed by inversion. At this time, the final concentrations were 10μM for KIF, 100μM for DMJ, SWA, and ManA, and 25μM for compounds (a1-1) to (a1-8). The compound-added cell suspension was added in an amount of 150 μL to each agarose-added plate. They were then transferred to a CO2 incubator and cultured under conditions of 37°C and 5% CO2. The morphology of the cells after 1 and 3 days of culture was observed with an inverted microscope and photographed. Furthermore, after observing and photographing the spheroids on the third day of culture with an inverted microscope, the medium in each well was adjusted to 100μL with a micropipette (NICHIRYO, Nichipet Premium LT, 00-NLT-200) and gently pipetted 10 times at a frequency of about once every 3 seconds, and left to stand for 5 minutes. The morphology of the cells was then observed with an inverted microscope and photographed.

[0153] The results are shown in Figure 3. In Figure 3, the disruptive activity of SPH is expressed as the degree of disruption relative to KIF, with + representing the degree of disruption. Inhibitors that showed no observed disruption are indicated as "none," inhibitors that showed the same degree of disruption as KIF are indicated as "+," inhibitors that showed more disruption than KIF and where cells were observed to be scattered around SPH are indicated as "++," and inhibitors that showed weakened cell adhesion and no trace of the original SPH structure are indicated as "+++." In Figure 3, "After PT" refers to the observation results after pipetting the spheroids on the third day of culture.

[0154] As a result, SPH-destructive activity was observed in the GMI inhibitors KIF and DMJ, but not in the GMII inhibitors SWA and ManA. Compounds (a1-1) to (a1-7) were confirmed to exhibit stronger SPH-destructive activity than KIF, and compound (a1-8) was confirmed to exhibit SPH-destructive activity equivalent to that of KIF. Compounds (a1-1) to (a1-8) were suggested to inhibit GMI and thereby destroy SPH.

[0155] [Experimental Example 4] (Evaluation of evasion of drug resistance) Using the procedure below, we compared the effects of the anticancer drug doxorubicin (DOX) on monolayer-cultured OVCAR-3 cells and OVCAR-3 cell organoids. Furthermore, we evaluated the circumvention of drug resistance in cell organoids for compounds (a1-1) to (a1-7).

[0156] The effect of DOX on monolayer-cultured OVCAR-3 cells was evaluated as follows. OVCAR-3 cells, 25 cm 2 The cells were cultured in a 25cm flask for 7 days. 2 The antibiotic-containing 10% FBS RPMI1640 medium was removed from the flask using an aspirator, and the flask was washed three times with 2 mL of PBS(-) warmed to 37°C. 2 mL of PET warmed to 37°C was added thereto, left to stand for 5 minutes, and gently shaken to detach the cells. 2 mL of antibiotic-free 10% FBS RPMI1640 medium was added to the resulting liquid to inactivate the trypsin in the PET. 4 mL of the resulting liquid was transferred to a 15 mL tube and centrifuged at 3,000 rpm and 25°C for 5 minutes. The supernatant was then removed, and 1 mL of antibiotic-free RPMI1640 medium was added and suspended to prepare a cell suspension. The cell density (cells / mL) of the obtained cell suspension was measured by counting, and the cell density was adjusted. OVCAR-3 cells were added to each well of a 96-well plate (CORNING, 353072) at a concentration of 1.0 × 10 4The cell suspension (100 μL) was added so that each well of the 96-well plate was 1. The 96-well plate was then transferred into a CO incubator and cultured at 37° C. and 5% CO for 24 hours.

[0157] DOX solutions (0.02, 0.1, 0.2, 1, and 2 mM) were prepared using DMSO. The DOX solutions of each concentration were diluted with antibiotic-free 10% FBS RPMI1640. The final concentrations of DOX were 0.1, 0.5, 1, 5, and 10 μM. Next, the medium in each well of the 96-well plate was removed using an aspirator, and then 100 μL of each diluted DOX solution was added to each well.

[0158] The 96-well plate was transferred to a CO2 incubator and incubated at 37°C and 5% CO2 for 72 hours, after which 10 μL of CCK-8 solution was added to each well. The 96-well plate was then transferred to a CO2 incubator and incubated at 37°C and 5% CO2 for 2 hours. The absorbance at 450 nm was measured using a microplate reader (iMark, 2009-231-0000496) with the absorbance at 650 nm as the reference wavelength. The cell viability was calculated based on the absorbance measurements.

[0159] From the calculated cell viability, the 50% cytotoxic concentration (CC) of DOX in monolayer cultured OVCAR-3 cells was 50 ) was confirmed to be 0.33 μM.

[0160] OVCAR-3 cell organoids were generated by the following procedure. OVCAR-3 cells in two 75 cm 2 The cells were cultured in a 75cm flask for 7 days. 2The antibiotic-containing 10% FBS RPMI1640 medium was removed from the flask using an aspirator, and the flask was washed three times with 6 mL of PBS(-) warmed to 37°C. 6 mL of PET warmed to 37°C was added thereto, left to stand for 5 minutes, and gently shaken to detach the cells. 6 mL of antibiotic-free 10% FBS RPMI1640 medium was added to the resulting liquid to inactivate the trypsin in the PET. 24 mL of the resulting liquid was transferred to a 50 mL tube and centrifuged at 3,000 rpm and 25°C for 5 minutes. The supernatant was then removed, and 1 mL of antibiotic-free RPMI1640 medium was added and suspended to prepare a cell suspension. The cell density (cells / mL) of the obtained cell suspension was measured by counting, and the cell density was adjusted. OVCAR-3 cells were placed in a Cellbed 96-well plate (Japan Vilene Co., Ltd., CB-96WT1) at 1.0 × 10 per well. 5 200 μL of the cell suspension was added to each well so that there were 10 cells / well.

[0161] The 96-well plate was then transferred to a CO2 incubator and cultured for 6 days at 37°C with 5% CO2, changing the medium every 2 days (2nd to 4th days of culture) to produce OVCAR-3 cell organoids. When changing the medium, the tip of the aspirator or pipette was aligned along the wall of the well so as not to damage the Cellbed attached to the bottom of the well with the tip of the aspirator or pipette, and the medium was removed using a tabletop aspirator with low suction power (BIOSAN LTD., BS-040108-AAK) while taking care not to suck up too much of the solution in the Cellbed at the bottom and dry it out, and then medium was added.

[0162] DOX solutions (0.02, 0.1, 0.2, 1, and 2 mM) were prepared using DMSO. The prepared DOX solutions of each concentration were diluted with 10% FBS without antibiotics. The final concentrations of DOX were 0.1, 0.5, 1, 5, and 10 μM. On the sixth day after the start of culture, the medium in each well of the 96-well plate was removed with an aspirator, and then 200 μL of each diluted DOX solution was added to each well. The cells were cultured for 72 hours under conditions of 37°C and 5% CO2.

[0163] CCK-8 solution and antibiotic-free 10% FBS RPMI1640 medium were mixed to prepare WST-8 solution (CCK-8 solution: antibiotic-free 10% FBS RPMI1640 medium = 1:9). 72 hours after DOX administration, the medium in each well of the 96-well plate was removed with an aspirator, and 200 μL of WST-8 solution was added to each well. The 96-well plate was then transferred to a CO2 incubator and cultured for 2 hours under conditions of 37°C and 5% CO2. The culture supernatant was dispensed in 100 μL portions into a 96-well plate (ThermoScientific, 260860), and the absorbance at 450 nm was measured using a microplate reader (iMark, 2009-231-0000496) with the absorbance at 650 nm as the reference wavelength. The cell viability was calculated based on the absorbance measurements.

[0164] The calculated cell viability indicated that CC of DOX in OVCAR-3 cell organoids was significantly improved by 50 was confirmed to be 4.53 μM.

[0165] Using DMSO, DOX solutions (0.04, 0.2, 0.4, 2, 4 mM), KIF (4 mM), and compounds (a1-1) to (a1-7) (10 mM) were prepared, and these were diluted with antibiotic-free 10% FBS RPMI1640. The final concentration of DOX in each solution was 0.1, 0.5, 1, 5, or 10 μM. Each solution was prepared to contain either KIF (final concentration: 10 μM) or compounds (a1-1) to (a1-7) (final concentration: 25 μM). On the sixth day after the start of culture, the medium in each well of the 96-well plate was removed using an aspirator, and 200 μL of each diluted DOX solution was added to each well. The cells were cultured for 72 hours under conditions of 37°C and 5% CO2.

[0166] 72 hours after administration of DOX and KIF or compounds (a1-1) to (a1-7), the medium in each well of the 96-well plate was removed with an aspirator, and 200 μL of WST-8 solution was added to each well. The 96-well plate was then transferred to a CO2 incubator and cultured for 2 hours under conditions of 37°C and 5% CO2. The culture supernatant was dispensed into 96-well plates in 100 μL portions, and the absorbance at 450 nm was measured using a microplate reader with the absorbance at 650 nm as the reference wavelength. The cell viability was calculated based on the absorbance measurements. Furthermore, the reduction rate of the anticancer drug DOX was calculated using the following formula. The results are shown in Table 2. (Reduction rate of anticancer drug DOX) = 100 - (CC when KIF or compounds (a1-1) to (a1-7) were administered 50 ) / (CC when KIF or compounds (a1-1) to (a1-7) are not administered 50 ) CC without administration of KIF or compounds (a1-1) to (a1-7) 50 is 4.53 μM.

[0167] [Table 2]

[0168] When the compounds (a1-1) to (a1-7) were used, CC 50 It was also revealed that when compounds (a1-1) to (a1-7) were used, the same effect could be obtained even if the amount of DOX used was reduced by 23 to 57%. [Industrial Applicability]

[0169] According to the present invention, it is possible to provide a compound capable of suppressing adhesion between tumor cells and having reduced cytotoxicity, a tumor lytic agent containing, as an active ingredient, the compound or a salt thereof, or a solvate of either, and a pharmaceutical composition containing the tumor lytic agent. The present invention can be suitably used in the treatment of cancer.

Claims

1. A compound represented by the following general formula (a0): [Case 1] [In the formula, R 1 R is an alkoxy group, an alkyl group, or a hydrogen atom. 2 is a hydrocarbon group which may have a substituent.

2. The compound according to claim 1, which is a compound represented by the following general formula (a1): [Case 2] [In the formula, R 11 is an alkoxy group having 1 to 3 carbon atoms or a hydrogen atom. 21 is a halogen atom, an alkyl group having 1 to 3 carbon atoms, a halogenated alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a nitro group. 2 is an integer from 0 to 5. 2 is an integer of 2 or more, a plurality of R 21 may be the same or different.

3. In the general formula (a1), R 11 is a methoxy group, R 21 is a halogen atom, a methyl group, a halogenated methyl group, a methoxy group, or a nitro group.

4. A tumor lytic agent comprising the compound or a salt thereof, or a solvate of the compound or the salt according to any one of claims 1 to 3 as an active ingredient.

5. 5. A pharmaceutical composition for treating tumors comprising an effective amount of an oncolytic agent according to claim 4 and a pharma- ceutically acceptable carrier.

6. The pharmaceutical composition according to claim 5 , wherein the tumor is a solid malignant tumor and is used in combination with an anticancer agent.